Want to see HK:8189 full AI Analyst Report?
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H (8189) Ratios
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Ratios
HK:8189's free cash flow for Q2 2026 was $35.80M. For the 2026 fiscal year, HK:8189's free cash flow was decreased by $-1.37M and operating cash flow was $37.17M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.75 | 0.84 | 0.88 | 0.88 | 1.09 |
| Quick Ratio | 0.19 | 0.57 | 0.46 | 0.55 | 0.70 |
| Cash Ratio | 0.12 | 0.09 | 0.03 | 0.03 | 0.14 |
| Solvency Ratio | -0.30 | -0.06 | -0.04 | -0.05 | -0.14 |
| Operating Cash Flow Ratio | -0.22 | -0.09 | -0.06 | -0.06 | -0.03 |
| Short-Term Operating Cash Flow Coverage | -0.56 | -0.20 | -0.21 | -0.20 | -0.16 |
| Net Current Asset Value | $ -72.52M | $ -70.09M | $ -48.36M | $ -60.41M | $ -28.49M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.41 | 0.48 | 0.28 | 0.30 | 0.26 |
| Debt-to-Equity Ratio | 8.98 | 7.22 | 1.67 | 1.46 | 0.90 |
| Debt-to-Capital Ratio | 0.90 | 0.88 | 0.63 | 0.59 | 0.47 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.40 | 0.17 | 0.00 | 0.06 |
| Financial Leverage Ratio | 21.67 | 15.01 | 6.07 | 4.81 | 3.45 |
| Debt Service Coverage Ratio | -0.14 | -0.14 | 0.09 | -0.03 | -0.64 |
| Interest Coverage Ratio | -6.39 | -6.20 | -1.90 | -3.81 | -3.36 |
| Debt to Market Cap | 0.17 | 0.28 | 0.42 | 0.19 | 0.18 |
| Interest Debt Per Share | 0.05 | 0.09 | 0.05 | 0.06 | 0.05 |
| Net Debt to EBITDA | -5.72 | -6.66 | 16.19 | -42.29 | -2.14 |
| Profitability Margins | |||||
| Gross Profit Margin | 6.82% | 4.40% | 5.37% | 3.67% | 9.57% |
| EBIT Margin | -4.63% | -7.36% | -1.72% | -4.37% | -8.26% |
| EBITDA Margin | -2.76% | -5.24% | 1.20% | -0.56% | -6.27% |
| Operating Profit Margin | -4.63% | -7.36% | -2.47% | -6.05% | -3.86% |
| Pretax Profit Margin | -21.60% | -9.91% | -3.02% | -5.96% | -9.41% |
| Net Profit Margin | -17.37% | -7.21% | -5.07% | -6.80% | -8.87% |
| Continuous Operations Profit Margin | -21.71% | -9.85% | -2.76% | -5.83% | -9.40% |
| Net Income Per EBT | 80.42% | 72.77% | 167.82% | 114.12% | 94.24% |
| EBT Per EBIT | 466.79% | 134.60% | 122.14% | 98.53% | 243.83% |
| Return on Assets (ROA) | -33.39% | -8.36% | -6.65% | -8.14% | -12.16% |
| Return on Equity (ROE) | -723.42% | -125.52% | -40.36% | -39.15% | -41.93% |
| Return on Capital Employed (ROCE) | -181.06% | -53.09% | -11.38% | -20.53% | -11.82% |
| Return on Invested Capital (ROIC) | -20.64% | -14.88% | -6.00% | -12.83% | -9.15% |
| Return on Tangible Assets | -35.07% | -8.70% | -6.95% | -8.81% | -12.66% |
| Earnings Yield | -15.53% | -5.13% | -11.86% | -8.21% | -16.11% |
| Efficiency Ratios | |||||
| Receivables Turnover | 27.91 | 35.63 | 45.35 | 12.67 | 14.85 |
| Payables Turnover | 21.28 | 41.26 | 23.38 | 20.91 | 14.59 |
| Inventory Turnover | 3.34 | 4.89 | 4.16 | 5.85 | 5.73 |
| Fixed Asset Turnover | 6.79 | 3.92 | 3.99 | 3.41 | 3.81 |
| Asset Turnover | 1.92 | 1.16 | 1.31 | 1.20 | 1.37 |
| Working Capital Turnover Ratio | -9.49 | -10.77 | -15.40 | -95.56 | 11.54 |
| Cash Conversion Cycle | 105.28 | 75.99 | 80.10 | 73.69 | 63.29 |
| Days of Sales Outstanding | 13.08 | 10.24 | 8.05 | 28.81 | 24.58 |
| Days of Inventory Outstanding | 109.36 | 74.59 | 87.66 | 62.34 | 63.74 |
| Days of Payables Outstanding | 17.15 | 8.85 | 15.61 | 17.46 | 25.02 |
| Operating Cycle | 122.44 | 84.83 | 95.71 | 91.15 | 88.32 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.03 | -0.01 | -0.01 | -0.01 | -0.00 |
| Free Cash Flow Per Share | -0.03 | -0.02 | -0.01 | -0.01 | -0.02 |
| Dividend Paid and CapEx Coverage Ratio | -6.61 | -10.27 | -5.33 | -1.46 | -0.20 |
| Capital Expenditure Coverage Ratio | -6.61 | -10.27 | -5.33 | -1.46 | -0.20 |
| Operating Cash Flow Coverage Ratio | -0.50 | -0.16 | -0.16 | -0.12 | -0.07 |
| Operating Cash Flow to Sales Ratio | -0.11 | -0.07 | -0.03 | -0.03 | -0.01 |
| Free Cash Flow Yield | -11.03% | -5.32% | -9.19% | -6.46% | -15.40% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -6.43 | -19.51 | -8.43 | -12.19 | -6.21 |
| Price-to-Sales (P/S) Ratio | 1.12 | 1.41 | 0.43 | 0.83 | 0.55 |
| Price-to-Book (P/B) Ratio | 46.59 | 24.48 | 3.40 | 4.77 | 2.60 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -9.07 | -18.81 | -10.88 | -15.48 | -6.50 |
| Price-to-Operating Cash Flow Ratio | -10.44 | -20.64 | -12.92 | -26.09 | -39.24 |
| Price-to-Earnings Growth (PEG) Ratio | -0.04 | -0.19 | 0.20 | 0.30 | 0.52 |
| Enterprise Value Multiple | -46.20 | -33.53 | 51.65 | -190.06 | -10.92 |
| Enterprise Value | 650.28M | 676.81M | 247.60M | 430.32M | 326.19M |
| EV to EBITDA | -46.20 | -33.53 | 51.65 | -190.06 | -10.92 |
| EV to Sales | 1.28 | 1.76 | 0.62 | 1.07 | 0.68 |
| EV to Free Cash Flow | -10.35 | -23.48 | -15.85 | -19.90 | -8.08 |
| EV to Operating Cash Flow | -11.91 | -25.76 | -18.82 | -33.56 | -48.80 |
| Tangible Book Value Per Share | -0.00 | 0.01 | 0.03 | 0.03 | 0.05 |
| Shareholders’ Equity Per Share | 0.01 | 0.01 | 0.03 | 0.04 | 0.05 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.01 | 0.01 | 0.09 | 0.02 | 0.00 |
| Revenue Per Share | 0.24 | 0.22 | 0.21 | 0.21 | 0.25 |
| Net Income Per Share | -0.04 | -0.02 | -0.01 | -0.01 | -0.02 |
| Tax Burden | 0.80 | 0.73 | 1.68 | 1.14 | 0.94 |
| Interest Burden | 4.67 | 1.35 | 1.76 | 1.36 | 1.14 |
| Research & Development to Revenue | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 |
| SG&A to Revenue | 0.06 | 0.09 | 0.05 | 0.07 | 0.07 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.48 | 0.72 | 0.75 | 0.48 | 0.15 |
Currency in CNY
